/GLS
GLS Stock - Gelesis Holdings, Inc.
Healthcare|BiotechnologyNYSE
$0.16+0.00%
+$0.00 (+0.00%) • Apr 10
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GLS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.16 – $0.16
TARGET (TP)$0.18
STOP LOSS$0.15
RISK/REWARD1:2.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.99
52W High$5.67
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $25.77M | $11.19M |
| Gross Profit | $-1,791,000 | $1.20M |
| Gross Margin | -7.0% | 10.7% |
| Operating Income | $-121,806,000 | $-84,973,000 |
| Net Income | $-55,780,000 | $-93,347,000 |
| Net Margin | -216.5% | -834.6% |
| EPS | $-0.79 | $-16.34 |
Company Overview
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
GLSBeat Rate
50%
Last 2 quarters
Avg Surprise
+6.5%
EPS vs Estimate
Beats / Misses
1/1
Last 12 quarters
Latest EPS
$-0.10
Q3 2023
EPS Surprise History
Q3 21
No data
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q4 22
+41.2%
$-0.20vs$-0.34
Q1 23
-28.1%
$-0.33vs$-0.26
Q2 23
No data
Q3 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Mar 26, 2024 | — | — | — | — |
Q4 2023 | Nov 13, 2023 | — | — | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.10 | — | — |
Q2 2023 | May 10, 2023 | — | $-0.07 | — | — |
Q1 2023 | Mar 28, 2023 | $-0.26 | $-0.33 | -28.1% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.34 | $-0.20 | +41.2% | ✓ BEAT |
Q3 2022 | Sep 16, 2022 | — | $-0.17 | — | — |
Q2 2022 | Jun 23, 2022 | — | $-0.09 | — | — |
Q1 2022 | Mar 24, 2022 | — | $-0.09 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.43 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.34 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.26 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about GLS
What is GLS's current stock price?
Gelesis Holdings, Inc. (GLS) is currently trading at $0.16 per share. The stock has moved +0.00% today.
What is the analyst price target for GLS?
No analyst price targets are currently available for this stock.
What sector is Gelesis Holdings, Inc. in?
Gelesis Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is GLS's market cap?
Gelesis Holdings, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does GLS pay dividends?
No, Gelesis Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMTI
Applied Molecular Transport Inc.
$0.26
Mkt Cap: $0.0B
AXLA
Axcella Health Inc.
$4.58
Mkt Cap: $0.0B
CYCC
Cyclacel Pharmaceuticals, Inc.
$6.37
Mkt Cap: $0.0B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
NTBL
Notable Labs, Ltd.
$0.25
Mkt Cap: $0.0B
OBSV
ObsEva S.A.
$0.10
Mkt Cap: $0.0B
SCPX
Scorpius Holdings, Inc.
$0.00
Mkt Cap: $0.0B
SQZB
SQZ Biotechnologies Company
$0.02
Mkt Cap: $0.0B
Explore stocks similar to GLS for comparison